BioPharma Resources

Drug Trial Radar · NCT03683251

Extension Study for the Port Delivery System With Ranibizumab (Portal)

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Portal)

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Sep 20, 2018

Primary completion

Dec 31, 2029

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Sep 25, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.

Conditions

  • Neovascular Age-Related Macular Degeneration

Interventions

  • PDS Implant with Ranibizumab 100 mg/mLDrug

    Will be administered as per the schedule described in individual arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of Ocular and Systemic (Non-Ocular) Adverse Events (AEs)Time frame: Baseline up to Week 240
  2. Incidence, Severity, and Duration of Adverse Event of Special Interest (AESIs)Time frame: Baseline up to Week 240
  3. Incidence, Severity, and Duration of PDS-Associated Ocular AESIs During the Postoperative Period (Up to 37 days of Initial Implantation) and Follow-Up Period (>37 days After Implantation Surgery) for Participants who Receive the PDS Implant in the StudyTime frame: Baseline up to Week 240
  4. Incidence and Severity of Adverse Device EffectsTime frame: Baseline up to Week 240
  5. Incidence, Causality, Severity, And Duration Of Anticipated Serious Adverse Device EffectsTime frame: Baseline up to Week 240
  6. Sub-study 1: Rate of Vitreous Hemorrhage Secondary to Choroidal Bleeding That Does not Resolve by the Week 4 Visit After Implant Insertion Surgery.Time frame: Baseline to Week 4
  7. Sub-study 2: Number of Participants with Ocular and Systemic (Non-ocular) Adverse Events (AEs) and Severity of These AEsTime frame: Baseline to Week 72
  8. Sub-study 2: Number of Participants with Adverse Events of Special Interests (AESIs) and Severity of AESIsTime frame: Baseline to Week 72
  9. Sub-study 2: Duration of AESIsTime frame: Baseline to Week 72
  10. Sub-study 2: Number of participants with Ocular AESIs and Severity of Ocular AESIs During the Post-operative PeriodTime frame: Up to Day 37 post re-implantation
  11. Sub-study 2: Number of participants with Ocular AESIs and Severity of Ocular AESIs During the Follow-up PeriodTime frame: > 37 days post re-implantation (up to approximately Week 72)
  12. Sub-study 2: Duration of Ocular AESIs During the Post-operative PeriodTime frame: Up to Day 37 post re-implantation
  13. Sub-study 2: Duration of Ocular AESIs During the Follow-up PeriodTime frame: > 37 days post re-implantation (up to approximately Week 72)
  14. Sub-study 2: Number of Participants with Adverse Device Effects (ADEs) and Severity of ADEsTime frame: Baseline to Week 72
  15. Sub-study 2: Number of Participants with Anticipated Serious ADEs and Severity of Anticipated Serious ADEsTime frame: Baseline to Week 72
  16. Sub-study 2: Duration of Anticipated Serious ADEsTime frame: Baseline to Week 72
  17. Sub-study 2: Number of Device DeficienciesTime frame: Baseline to Week 72

Locations

165 sites in 15 countries. Site status is shown where the registry gives one.

  • Retinal Research Institute, LLC

    Phoenix, Arizona · Completed

  • Arizona Retina and Vitreous Consultants

    Phoenix, Arizona · Completed

  • Barnet Dulaney Perkins Eye Center

    Phoenix, Arizona · Active not recruiting

  • Associated Retina Consultants

    Phoenix, Arizona · Completed

  • Retinal Consultants of Arizona

    Phoenix, Arizona · Completed

  • California Retina Consultants

    Bakersfield, California · Completed

  • Retina-Vitreous Associates Medical Group

    Beverly Hills, California · Completed

  • The Retina Partners

    Encino, California · Active not recruiting

  • Jacobs Retina center at the Shiley eye Institute UCSD

    La Jolla, California · Completed

  • Jules Stein Eye Institute/ UCLA

    Los Angeles, California · Completed

  • N CA Retina Vitreous Assoc

    Mountain View, California · Completed

  • Retina Consultants, San Diego

    Poway, California · Completed

  • Retinal Consultants Med Group

    Sacramento, California · Completed

  • West Coast Retina Medical Group

    San Francisco, California · Completed

  • UCSF

    San Francisco, California · Completed

  • Orange County Retina Med Group

    Santa Ana, California · Active not recruiting

  • California Retina Consultants

    Santa Barbara, California · Completed

  • Southwest Retina Consultants

    Durango, Colorado · Completed

  • Eye Center of Northern CO

    Fort Collins, Colorado · Completed

  • Colorado Retina Associates, PC

    Lakewood, Colorado · Completed

  • Retina Group of New England

    Waterford, Connecticut · Completed

  • Florida Eye Microsurgical Inst

    Boynton Beach, Florida · Completed

  • National Ophthalmic Research Institute

    Fort Myers, Florida · Completed

  • Florida Eye Associates

    Melbourne, Florida · Completed

  • Retina Care Specialists

    Palm Beach Gardens, Florida · Completed

  • Retina Specialty Institute

    Pensacola, Florida · Completed

  • Fort Lauderdale Eye Institute

    Plantation, Florida · Completed

  • Retina Vitreous Assoc of FL

    St. Petersburg, Florida · Active not recruiting

  • Southern Vitreoretinal Assoc

    Tallahassee, Florida · Active not recruiting

  • Retina Associates of Florida, LLC

    Tampa, Florida · Completed

  • Southeast Retina Center

    Augusta, Georgia · Completed

  • Georgia Retina PC

    Marietta, Georgia · Withdrawn

  • Illinois Retina Associates

    Joliet, Illinois · Completed

  • University Retina and Macula Associates, PC

    Oak Forest, Illinois · Completed

  • Wolfe Eye Clinic

    West Des Moines, Iowa · Completed

  • Retina Associates

    Lenexa, Kansas · Completed

  • Retina Associates of Kentucky

    Lexington, Kentucky · Completed

  • Paducah Retinal Center

    Paducah, Kentucky · Withdrawn

  • Maine Eye Center

    Portland, Maine · Completed

  • The Retina Care Center

    Baltimore, Maryland · Completed

Showing 40 of 165 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.